Pfizer UK has announced that it has signed an exclusive agreement with Novartis to market the Ultibro Breezhaler indacaterol/glycopyrronium DPI and the Seebri Breezhaler glycopyrronium DPI in the UK for the treatment of COPD.
Seebri Breezhaler was approved in Europe in October 2012 and has been available in the UK since November of that year. Ultibro Breezhaler was approved by the EU in September 2013 but is not yet marketed in the UK.
According to the announcement, Novartis will continue to have responsibility for manufacturing, sales, distribution, and regulatory commitments for both drugs, while Pfizer will have responsibility for marketing and promotional activities.
Pfizer UK Managing Director Jonathan Emms commented, “This deal is good news for UK patients, as well as for both organizations. COPD is a debilitating disease which can have a significant impact on the lives of patients, so this agreement will enable us to use our considerable expertise in this area to bring these medicines to the UK clinicians and patients who need them.”
Read the Pfizer press release.
